Potentiation of bleomycin by an antifungal polyene, pentamycin, in transformed animal cells. 1974

T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011090 Polyenes Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES. Cumulenes
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005672 Fusidic Acid An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis. Fucithalmic,Fusidate Sodium,Fusidic Acid, Sodium Salt,Fusidin,Silver Fusidate,Sodium Fusidate,Stanicide,Acid, Fusidic,Fusidate, Silver,Fusidate, Sodium,Sodium, Fusidate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
January 1965, Medicina et pharmacologia experimentalis. International journal of experimental medicine,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
May 1973, Antimicrobial agents and chemotherapy,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
January 2012, Biological & pharmaceutical bulletin,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
April 1974, Il Farmaco; edizione scientifica,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
December 1979, Cancer research,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
February 1982, Cancer treatment reports,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
January 1975, Journal of the National Cancer Institute,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
April 2019, Bulletin of experimental biology and medicine,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
September 2009, Arhiv za higijenu rada i toksikologiju,
T Nakashima, and M Kuwano, and K Matsui, and S Komiyama, and I Hiroto
June 1990, Science (New York, N.Y.),
Copied contents to your clipboard!